Pulmonary Fibrosis

Respiratory·MeSH: Pulmonary Fibrosis

Prevalence

5.0 / 100K

40 drugs in development·29 companies·4 clinical trials

Drug Pipeline by Phase

Approved(7)

Drug	Company
etorel	GYRE THERAPEUTICS, INC. (GYRE)
nintedanib	X4 Pharmaceuticals, Inc (XFOR)
nintedanib	NYMOX PHARMACEUTICAL CORP (NYMXF)
nintedanib	Aptinyx Inc. (APTX)
nintedanib	EXELIXIS, INC. (EXEL)
nintedanib	DR REDDYS LABORATORIES LTD (RDY)
pirfenidone	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(5)

Phase 2(12)

Drug	Company
Bexotegrast (PLN-74809)	PLIANT THERAPEUTICS, INC. (PLRX)
env-101	Generate Biomedicines Inc. (GENB)
gri-0621	GRI Bio, Inc. (GRI)
ifetroban	CUMBERLAND PHARMACEUTICALS INC (CPIX)
lti-03	Rein Therapeutics, Inc. (RNTX)
mn-001	MEDICINOVA INC (MNOV)
nal er	Trevi Therapeutics, Inc. (TRVI)
pipe-791 dose a	Contineum Therapeutics, Inc. (CTNM)
pipe-791 dose b	Contineum Therapeutics, Inc. (CTNM)
PLN-74809	PLIANT THERAPEUTICS, INC. (PLRX)
tti-101	Tvardi Therapeutics, Inc. (TVRD)
Vasculan	CUMBERLAND PHARMACEUTICALS INC (CPIX)

Phase 1(8)

Drug	Company
ABBV-142	AbbVie Inc. (ABBV)
ANPA-0073	Structure Therapeutics Inc. (GPCR)
ARO-MMP7	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARO-MMP7 Inhalation Solution	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
Axatilimab	Syndax Pharmaceuticals Inc (SNDX)
deupirfenidone	PureTech Health plc (PRTC)
mnkd-201	MANNKIND CORP (MNKD)
nintedanib	SUNSHINE BIOPHARMA INC. (SBFM)

Preclinical(5)

Drug	Company
ATYR0101	aTYR PHARMA INC (ATYR)
cb5138-3	COHBAR, INC. (COBU)
chit1 small molecule	Ocean Biomedical, Inc. (OCEA)
LTSE-2578	Structure Therapeutics Inc. (GPCR)
REC-4209	RECURSION PHARMACEUTICALS, INC. (RXRX)

Phase 4(3)

Drug	Company
BMS-986278	BRISTOL MYERS SQUIBB CO (BMY)
inhaled treprostinil	UNITED THERAPEUTICS Corp (UTHR)
Inhaled treprostinil	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 40 drugs in development for Pulmonary Fibrosis across 29 companies.

There are 4 clinical trials targeting Pulmonary Fibrosis tracked by BioSniper.

The estimated prevalence of Pulmonary Fibrosis is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.